BPC-157: What the Research Says

BLUF

BPC-157 is a synthetic 15-amino-acid peptide (“pentadecapeptide,” research code PL-14736 / PLD-116) derived from a sequence found in human gastric juice. In animal models, published studies have repeatedly observed effects on tissue repair, blood-vessel formation (angiogenesis), and the nitric-oxide system across the gut, tendon, muscle, and vascular systems. That body of work is large but dominated by a small number of research groups and almost entirely preclinical. Human evidence is minimal: as of this writing there are only a handful of registered or reported human studies, and BPC-157 remains an unapproved research compound. The honest summary: interesting and consistent signals in rodents; the human translation is largely unproven. This page documents what the studies actually report — and where the gaps are.

What BPC-157 is

BPC-157 (Body Protection Compound-157) is a partial sequence of a protein originally isolated from human gastric juice. It is sometimes called a “stable gastric pentadecapeptide” in the literature because, unlike many peptides, it is reported to remain stable in gastric acid.

Verified chemistry (research-database sourced — this is not a dosing table).

(All identifiers above are retrieved verbatim from PubChem and ChEMBL on 2026-06-08 — see References R1–R2.)

The evidence landscape — read this before anything else

This is the single most important thing to understand about BPC-157, and most pages online bury it:

• The vast majority of BPC-157 studies are in rats and mice, or in cell culture. Animal-model results are a starting point for science, not proof of human benefit. Many compounds that look promising in rodents fail in humans.
• A large share of the published literature originates from a relatively concentrated set of research groups (notably the Sikiric group and collaborators). Independent replication across many labs is far thinner than the raw publication count suggests. A 2025 literature-and-patent review and a published scientific exchange between research groups (Józwiak et al. vs. Sikiric et al.) make this debate explicit. [R3, R4, R5]
• Human trials are scarce. Registered human studies number in the low single digits (see “Human data” below).

So what: when you read “BPC-157 heals tendons,” the accurate translation is “studies have observed accelerated tendon-healing markers in rats.” That distinction is the entire point of this page.

Mechanisms the research describes

Published work proposes several mechanisms — described here as what researchers report, not as established human pharmacology:

• Angiogenesis (new blood-vessel formation). Multiple papers from the originating research groups center BPC-157’s reported effects on promoting angiogenesis and modulating the nitric-oxide (NO) system. A 2025 review/commentary frames BPC-157’s proposed action specifically around angiogenesis and the NO pathway. [R5]
• Growth-factor and pathway signaling. Reviews describe involvement of growth-factor receptor pathways (e.g., VEGFR2) and effects on collagen organization in soft-tissue healing models. [R6, R7]
• Cytoprotection. The “body protection compound” naming reflects reported protective effects on the gastrointestinal lining and other tissues against various insults in animal models. [R8]

Each of these is observed in animal/in-vitro systems. None is established as a clinical mechanism of action in humans.

What’s been studied, by research area

Every line below is phrased as the literature actually supports it: studies observed X in [model].

• Gastrointestinal. The original and most-developed line of research. Animal studies report protective and healing effects on the GI tract, and one human-oriented development line (as PL-14736) was explored for inflammatory bowel disease. [R8, and the registered Phase-1/PK trial below]
• Tendon & ligament. Rodent studies report accelerated tendon and ligament healing markers; recent orthopedic/sports-medicine reviews catalog this preclinical work and explicitly flag the lack of human trials. [R6, R7, R9]
• Muscle & muscle-to-bone. Rat studies report improved outcomes after surgical muscle detachment/reattachment models. [R10]
• Vascular / ischemia-reperfusion. Recent rat studies report protective effects in lower-extremity ischemia-reperfusion injury and aortic-wall remodeling models. [R11, R12]
• Neurological / analgesia. A 2026 review discusses BPC-157’s reported role spanning tissue repair to pain modulation — again, predominantly preclinical. [R13]
• Cornea / ophthalmic. A 2025 conceptual framework paper discusses BPC-157 in corneal-ulcer and neovascularization models. [R14]
• Electrolyte / systemic. A 2026 rat study reports effects in severe electrolyte-disturbance models. [R15]
• Aging / longevity context. A 2026 gerontology review situates BPC-157 among “therapeutic peptides” being explored for healthy aging — explicitly at the mechanism/exploration stage. [R16]

Human data — what little exists

This is short on purpose, because the human evidence base is short.

• NCT02637284 (PCO-02) — a registered Phase 1 “Safety and Pharmacokinetics” trial. Status listed as Unknown in the registry. [R17]
• NCT07437547 — a Phase 2 trial, “BPC 157 for Acute Hamstring Muscle Strain Repair,” listed as Recruiting. [R18]
• A 2025 human IV-infusion safety pilot study was published (small pilot; safety-focused, not an efficacy trial). [R19]

That is essentially the registered/published human picture. There is no large, replicated, randomized human efficacy trial for any indication as of this writing. Anyone citing BPC-157 “results” should be asked: in what species, in what model?

Safety & what is NOT known

• Reported animal toxicity is described as low across the originating literature, and the small human pilot focused on safety. [R19]
• But: “low toxicity in rats” is not a human safety profile. There is no long-term human safety data, no standardized pharmacovigilance, and research-market BPC-157 is not subject to pharmaceutical quality control — purity, identity, and contamination vary by source. Independent purity/identity verification is a known concern with research peptides generally.
• Unknowns include: long-term human effects, drug interactions, effects on neoplastic (cancer) tissue (a theoretical concern wherever angiogenesis is promoted), and reproductive/developmental effects.

So what: the responsible framing is “animal-safety signals are encouraging; human safety is essentially uncharacterized.”

Regulatory & legal status

• BPC-157 is not an FDA-approved drug and is not approved to treat any condition in humans.
• In the U.S. it is commonly sold labeled “for research use only.” It has been the subject of FDA attention in the context of compounding (FDA has placed certain substances into categories that restrict compounding); status can change — verify current regulatory status before relying on it.
• Sport: athletes should treat BPC-157 as prohibited-risk. WADA has signaled scrutiny of BPC-157; competitive athletes must check the current WADA Prohibited List directly rather than rely on any third-party summary.

(This site does not provide legal or regulatory advice; status is jurisdiction- and time-dependent.)

How researchers organize and track protocols

Researchers documenting BPC-157 work in a lab or research setting commonly need to compute reconstitution (how much bacteriostatic water to add to a lyophilized vial to reach a target concentration) and track that documentation precisely. Peptide Manager Pro provides a free, research-only BPC-157 dosage & reconstitution calculator and a calculadora de mezcla de BPC-157 + TB-500 for exactly this record-keeping purpose — for research documentation only, not a recommendation to administer anything. See also all peptide calculators y la simplified BPC-157 overview.

Preguntas Frecuentes

References

Database identity

• R1. PubChem Compound Summary, CID 9941957 (BPC-157). MF C62H98N16O22; MW ~1419.5; CAS 137525-51-0; synonyms PL-14736, PLD-116.
• R2. ChEMBL CHEMBL4297358 (BPC-157). full_mwt 1419.56; max_phase 1.0.

Reviews, mechanism & the scientific debate

• R3. Józwiak M, Bauer M, Kamysz W, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMID 40005999. DOI 10.3390/ph18020185.
• R4. Józwiak M, Bauer M, Kamysz W. Reply to Sikiric et al. … Comment on “Józwiak et al. Multifunctionality…”. Pharmaceuticals (Basel). 2025;18(10):1451. PMID 41155566. DOI 10.3390/ph18101451.
• R5. Sikiric P, Seiwerth S, Skrtic A, et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide’s Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. … Pharmaceuticals (Basel). 2025;18(10):1450. PMID 41155565. DOI 10.3390/ph18101450.
• R6. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. PMID 30915550. DOI 10.1007/s00441-019-03016-8.
• R7. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID 40756949. DOI 10.1177/15563316251355551.
• R8. Yuan C, Demers A, Silva-Ortiz V, et al. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. Int J Mol Sci. 2026;27(6):2876. PMID 41898733. DOI 10.3390/ijms27062876.

Orthopedic / sports-medicine context (flags the human-evidence gap)

• R9. Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026. PMID 41476424. DOI 10.1177/03635465251357593.
• R9b. DeFoor MT, Dekker TJ. Injectable Therapeutic Peptides—An Adjunct to Regenerative Medicine and Sports Performance? Arthroscopy. 2025. PMID 39265666. DOI 10.1016/j.arthro.2024.09.005.

Specific animal-model studies (illustrative; all preclinical)

• R10. Matek D, Matek I, Staresinic E, et al. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle … for Muscle-to-Bone Reattachment in Rats. Pharmaceutics. 2025;17(1):119. PMID 39861766. DOI 10.3390/pharmaceutics17010119.
• R11. Yıldırım AK, Demirtaş H, Özer A. Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. Sci Rep. 2026. PMID 42204242. DOI 10.1038/s41598-026-55449-1.
• R12. Smoday IM, Vukovic V, Oroz K, et al. FTIR Characterization of Aortic Wall Remodeling by Stable Gastric Pentadecapeptide BPC 157 After Unilateral Adrenalectomy in Rats. Pharmaceuticals (Basel). 2026;19(1):191. PMID 41599787. DOI 10.3390/ph19010191.
• R13. (Neuro/analgesia) see R8 — Yuan et al. 2026.
• R14. Masnec S, Kokot A, Kralj T, et al. Challenge of Corneal Ulcer Healing … Pentadecapeptide BPC 157 Efficacy. Pharmaceuticals (Basel). 2025;18(12):1822. PMID 41471311. DOI 10.3390/ph18121822.
• R15. Grubisic MM, Strbe S, Barisic I, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy of Severe Electrolyte Disturbances in Rats. Curr Neuropharmacol. 2026. PMID 41832718. DOI 10.2174/011570159X401706251126101531.
• R16. Mavrych V, Shypilova I, Bolgova O. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Front Aging. 2026. PMID 42021992. DOI 10.3389/fragi.2026.1790247.

Human / clinical

• R17. ClinicalTrials.gov NCT02637284 — PCO-02 — Safety and Pharmacokinetics Trial (Phase 1; status Unknown).
• R18. ClinicalTrials.gov NCT07437547 — BPC 157 for Acute Hamstring Muscle Strain Repair (Phase 2; Recruiting).
• R19. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. PMID 40131143.